Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treat-CMV
2022-500714-25-01Phase 3Authorised
- Sponsor
- UZ Leuven
- Start
- Aug 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of valaciclovir in congenital cytomegalovirus infection (cCMV), sponsored by UZ Leuven. Primary endpoint: Rate of vertical transmission. Planned start Aug 2023; status: authorised.
02
Drugs
valaciclovir
03
Conditions
congenital cytomegalovirus infection (cCMV)
Beyond the preview
Go deeper on 2022-500714-25-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500714-25-01.